Axsome (AXSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - Axsome Therapeutics reported $121.46 million in revenue for Q1 2025, a 62$0.80, improving from -$1.09 a year ago [1] - The revenue exceeded the Zacks Consensus Estimate of$119.49 million by 1.66%, and the EPS surpassed the consensus estimate of -$1.26 by 36.51$1.11 million, below the average estimate of $1.40 million from six analysts [4] - Product sales, net totaled$120.36 million, slightly above the average estimate of $117.91 million from six analysts [4] - Product sales for Auvelity reached$96.20 million, exceeding the two-analyst average estimate of $91.65 million [4] - Product sales for Sunosi were$25.20 million, also surpassing the two-analyst average estimate of $24.90 million [4] Stock Performance - Axsome's shares have returned +13.5% over the past month, compared to a +0.4% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]